Oncology

Meanwhile, the company’s lead CAR Macrophage candidate CT-0508, continues to show efficacy in multiple solid tumor trials.

The Associate Professor of Medicine at Harvard Medical School discussed upcoming research and strategies to combat present hurdles in the treatment field.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The company also plans to submit an MAA to the EMA in the first half of 2024.

The FDA has received reports of multiple T-cell malignancies in patients after approved CAR-T treatment.

Maria Pia Morelli, MD, PhD, assistant professor, MD Anderson Cancer Center, discussed her work on the EVEREST-1 trial of logic-gated CAR T-cell therapy currently being evaluated in colorectal and pancreatic cancers.

Review top news and interview highlights from the week ending November 24, 2023, including coverage from AHA 2023.

The new PDUFA date of lifileucel is set for Februrary 24, 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The date for the AdComm and the new PDUFA date are yet to be announced.

The PDUFA date for Iovance’s lead TIL lifileucel for melanoma was recently pushed back to February 24, 2024.

The associate professor at MD Anderson Cancer Center discussed his future outlook and goals for the field of sarcoma.

Review top news and interview highlights from the week ending November 17, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The medical oncologist at Moffitt Cancer Center spoke about A2 Bio’s A2B530 as part of a larger discussion of novel cell therapy approaches in solid tumors.

The median progression-free survival was 11 months and the SCG101 was well-tolerated.

Review top news and interview highlights from the week ending November 10, 2023.

Ben Creelan, MD, a medical oncologist at Moffitt Cancer Center, discussed several different approaches to cell therapy that could lead to new treatment options in the field.

The medical oncologist at Moffitt Cancer Center discussed 3 different approaches to cell therapy that could lead to new treatment options in the field.

Microsatellite instability (MSI) tumors are frequently found in people with Lynch syndrome, one of the most common hereditary colorectal cancers.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

BRL Medicine is also enrolling a phase 1/2 multicenter trial evaluating BRL-201 at lower dose ranges.

The BASECAMP-1 screening study has now identified 28 patients whose solid tumors are positive for HLA-A*02 LOH.

David Rawlings, MD, the director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute, discussed findings from several preclinical studies that could help push engineered B-cell therapies towards clinical trials.

The chief scientific officer at Omega Therapeutics discussed milestones Omega Therapeutics is looking forward to in the next year.

Patients with HNSCC had a median overall survival (OS) of 20.8 months and a 12-month OS rate of 59%.

In terms of safety, it was noted that repeated administration of CAR mRNA/LNP was well-tolerated by mice.

Review top news and interview highlights from the week ending Novmber 3, 2023.

The chief executive officer of Likarda discussed the company’s CSS technology and how it may reduce off-tissue effects.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.